In recent years, immunotherapy, mainly represented by immune checkpoint inhibitors, including PD-1/PD-L1 and CTLA-4 inhibitors, has been widely applied in the treatment of various cancers with satisfactory results, which has become an indelible milestone in tumor immunotherapy (36, 37). This evidence concerns the gene CTLA4 and cancer.